Giberson-Chen Carew, Liu Christina, Grisdela Phillip, Liu David, Model Zina, Steele Amy, Blazar Philip, Earp Brandon E, Zhang Dafang
Harvard Combined Orthopaedic Residency Program, Harvard Affiliated Hospitals, Boston, MA, USA.
Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Brigham and Women's Hospital, Boston, MA, USA.
Hand (N Y). 2024 Feb 15:15589447241232015. doi: 10.1177/15589447241232015.
Concerns regarding the ongoing opioid epidemic have led to heightened scrutiny of postoperative opioid prescribing patterns for common orthopedic surgical procedures. This study investigated patient- and procedure-specific risk factors for additional postoperative opioid rescue prescriptions following ambulatory cubital tunnel surgery.
A retrospective review was performed of patients who underwent cubital tunnel surgery at 2 academic medical centers between June 1, 2015 and March 1, 2020. Patient demographics, comorbidities, prior opioid history, and surgical variables were recorded. The primary outcome was postoperative rescue opioid prescription. Univariate and bivariate statistical analyses were performed.
Two hundred seventy-four patients were included, of whom 171 (62%) underwent in situ ulnar nerve decompression and 103 (38%) underwent ulnar nerve decompression with anterior transposition. The median postoperative opioid prescription amount was 90 morphine equivalent units (MEU) for the total cohort, 77.5 MEU for in situ ulnar nerve decompression, and 112.5 MEU for ulnar nerve decompression with transposition. Twenty-two patients (8%) required additional rescue opioid prescriptions postoperatively. Female sex, fibromyalgia, chronic opioid use, chronic pain diagnosis, and recent opioid were associated with the need for additional postoperative rescue opioid prescriptions.
While most patients do not require additional rescue opioid prescriptions after cubital tunnel surgery, chronic pain patients and patients with pain sensitivity syndromes are at risk for requiring additional rescue opioid prescriptions. For these high-risk patients, preoperative collaboration of a multidisciplinary team may be beneficial for developing a perioperative pain management plan that is both safe and effective.
对持续的阿片类药物流行的担忧导致对常见骨科手术术后阿片类药物处方模式的审查更加严格。本研究调查了门诊肘管手术后额外术后阿片类药物急救处方的患者和手术特定风险因素。
对2015年6月1日至2020年3月1日期间在2个学术医疗中心接受肘管手术的患者进行回顾性研究。记录患者的人口统计学、合并症、既往阿片类药物使用史和手术变量。主要结局是术后急救阿片类药物处方。进行了单因素和双因素统计分析。
纳入274例患者,其中171例(62%)接受原位尺神经减压,103例(38%)接受尺神经减压并向前移位。整个队列术后阿片类药物处方量中位数为90吗啡当量单位(MEU),原位尺神经减压为77.5 MEU,尺神经减压并移位为112.5 MEU。22例患者(8%)术后需要额外的急救阿片类药物处方。女性、纤维肌痛、慢性阿片类药物使用、慢性疼痛诊断和近期使用阿片类药物与术后需要额外的急救阿片类药物处方有关。
虽然大多数患者在肘管手术后不需要额外的急救阿片类药物处方,但慢性疼痛患者和疼痛敏感综合征患者有需要额外急救阿片类药物处方的风险。对于这些高危患者,多学科团队的术前协作可能有助于制定安全有效的围手术期疼痛管理计划。